CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia
Autor: | Rosa van Amerongen, Bas Kersten, Gert J. Ossenkoppele, Wendelien Zeijlemaker, Zinia J. Kwidama, Rolf Wouters, Gertjan J.L. Kaspers, Matthijs Valkering, Gerrit Jan Schuurhuis, Peter J. M. Valk, Diana Hanekamp, Jacqueline Cloos |
---|---|
Přispěvatelé: | Hematology, Hematology laboratory, CCA - Biomarkers, Pediatric surgery |
Rok vydání: | 2016 |
Předmět: |
Adult
Male 0301 basic medicine Adolescent CD33 CD34 Antigens CD34 CD38 Biology Flow cytometry Young Adult 03 medical and health sciences Bone Marrow immune system diseases Biomarkers Tumor medicine Humans Aged medicine.diagnostic_test hemic and immune systems Hematology Middle Aged ADP-ribosyl Cyclase 1 Leukemia Myeloid Acute Haematopoiesis 030104 developmental biology medicine.anatomical_structure Drug Resistance Neoplasm Immunology Neoplastic Stem Cells Cancer research Leukocyte Common Antigens Female sense organs Interleukin-3 receptor Bone marrow Neoplasm Recurrence Local Stem cell |
Zdroj: | Kersten, B, Valkering, M, Wouters, R, van Amerongen, R, Hanekamp, D, Kwidama, Z, Valk, P, Ossenkoppele, G, Zeijlemaker, W, Kaspers, G, Cloos, J & Schuurhuis, G J 2016, ' CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia ', British Journal of Haematology, vol. 173, no. 2, pp. 219-235 . https://doi.org/10.1111/bjh.13941 British Journal of Haematology, 173(2), 219-235. Wiley-Blackwell Publishing Ltd British Journal of Haematology, 173(2), 219-235. Wiley-Blackwell |
ISSN: | 0007-1048 |
Popis: | Chemotherapy resistant leukaemic stem cells (LSC) are thought to be responsible for relapses after therapy in acute myeloid leukaemia (AML). Flow cytometry can discriminate CD34(+) CD38(-) LSC and normal haematopoietic stem cells (HSC) by using aberrant expression of markers and scatter properties. However, not all LSC can be identified using currently available markers, so new markers are needed. CD45RA is expressed on leukaemic cells in the majority of AML patients. We investigated the potency of CD45RA to specifically identify LSC and HSC and improve LSC quantification. Compared to our best other markers (CLL-1, also termed CLEC12A, CD33 and CD123), CD45RA was the most reliable marker. Patients with high percentages (>90%) of CD45RA on CD34(+) CD38(-) LSC have 1·69-fold higher scatter values compared to HSC (P |
Databáze: | OpenAIRE |
Externí odkaz: |